About this episode
The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Get every episode summarized
Each time Exchanges publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Exchanges
Dipan Patel on Permira’s ‘Artisanal’ Approach to Private Equity
Exchanges
Sep 4, 202634:01completed
The Outlook for Data Center Power Demand as AI Token Use Grows
Exchanges
Sep 1, 202632:08pending
Building AI Systems for Capital Markets
Exchanges
Aug 24, 202626:34pending
Wellington’s Jean Hynes on the Art of Investing and Finding New Markets
Exchanges
Aug 18, 202643:47pending